



*ISSN 2570-5911*  
*(PRINT)*

*ISSN 2570-5903*  
*(ON-LINE)*

*DOI: 10.29256*

***BIOLOGICAL MARKERS IN  
FUNDAMENTAL AND CLINICAL  
MEDICINE***

***COLLECTION OF ABSTRACTS***

---

---

***VOL. 2***

***No 2, 2018***

Collection of abstracts "**Biological Markers in Fundamental and Clinical Medicine**" (*official specialized scientific journal of The Czech Republic, registration number MK CR E 22955*) by the publishing center of The ESCBM provides its lanes for information materials in the field of scientific research of modern biological markers in clinical and experimental medicine, pharmacy, and fundamental biology. The collection publishes abstracts of scientific and practical conferences, seminars, symposia, dedicated to the study of molecular-biochemical and functional markers, playing a role in pathogenesis, diagnosis, prognosis, as well as assessing the monitoring of the treatment effectiveness for the various systems and organs diseases. **Among the priority topics of the journal there is the research of molecular mechanisms of diseases pathogenesis, the study of the structure and functions of peptides, nucleic acids, nucleotides, lipids and other biologically active components of body cells.**

The collection is intended for fast and systematic publication of abstracts, containing the results of author's research, reviews highlighting major developments in the field of biological markers, short messages, new experimental and clinical studies, which use biological markers, as well as proposing new principles and methods for the study of biological markers.

The collection is published 4 times a year. Circulation - 200 copies.

## CONTENTS

CANDIDATE GENES OF CANCER AS A TARGET OF miRNA HOST GENES .....	6
Aisina D.E. al-Farabi Kazakh National University, Kazakhstan	
LDL PARTICLE SIZE AND LIPID PROFILE IN CHILDREN WITH TYPE 1 DIABETES .....	7
Topuzovska S., Tosheska K., Labudovic D.	
MIRNAS AND GENES PARTICIPATING IN THE DEVELOPMENT OF ESOPHAGEAL CANCER .....	8
Akimniyazova A.N., Niyazova R.Y., Ivashchenko A.T.	
ASSOCIATION OF miRNA AND TARGET GENES OF PARKINSON'S 1 DISEASE .....	9
Aralbayeva A., Kamenova S.U. <sup>1</sup> , Ivashchenko A.T., Akimniyazova A.N.	
BIOMARKERS IN CARDIAC SURGERY AND MYOCARDIAL REGENERATION AFTER CORONARY ARTERY BYPASS GRAFTING .....	11
Bunenkov N. S., Komok V. V., Kostevich V. A., Gorbunov N. P., Sokolov A. V. Shvetsov A. N. Lukashenko V. I.I, Siddikov A. M.I, Kobak A. E.I, Babeshin M. V.I, Bely S.A., Nemkov A. S. <sup>1</sup> Khubulava G. G.	
EXPANSION OF CD62L-EXPRESSING MYELOID-DERIVED SUPPRESSOR CELLS IN INFLAMMATION-RELATED TUMOR PROGRESSION .....	12
Abdolla N., Perfilyeva Y.V., Ostapchuk Y.O., Tleulieva R., Krasnoshtanov V.C., Belyaev N.N., M.A.Aitkhozhin's	
FEATURES OF CYTOKINE PROFILE AND ENDOTHELIAL FUNCTION IN COMORBID COURSE OF ESSENTIAL HYPERTENSION	13
Burmak Yu.G., Petrov Ye.Ye., Treumova S.I., Ivaniitskaya T.A.	
THE STATE OF LIPID METABOLISM, LIPID PEROXIDATION AND ANTIOXIDANT DEFENSE IN PATIENTS WITH CHRONIC OBSTRUCTIVE BRONCHITIS WITH HYPERTROPHY AND ATROPHY OF THE MYOCARDIUM .....	14
Boriak V.	
RELATION OF GROWTH-DIFFERENTIATION FACTOR-15 LEVELS AND NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS .....	15
Alexander A. Kremzer, Ivan M. Fushtey, Alexander A. Berezin	
MARKERS OF ENDOTHELIAL INJURIES IN PATIENTS WITH CORONARY HEART DISEASE AND AUTOIMMUNE THYROIDITIS	15
Chekalina N., Kazakov Yu., Vesnina L., Mamontova T., Yushchenko Yu., Berkalo L.	
PREDICTIVE RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN ON EFFECT OF GINKGO BILOBA EXTRACT-761 IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER .....	17
Jithendra Chimakurthy <sup>1*</sup> , Talasila Egk Murthy, Prakash V Diwan,	
THE LINK BETWEEN MTHFR C677T GENE POLYMORPHISM AND TYPE 2 DIABETES MELLITUS DEVELOPMENT IN UKRAINIAN POPULATION .....	18
Chumachenko Ya., Rusanov A., Dubovyk Ye., Harbuzova V.	
OXIDATIVE STRESS MARKERS OF BLOOD CELLS IN ACUTE ALCOHOL INTOXICATION .....	20
Demidchik L.	
THE SERUM CHEMILUMINESCENCE OF GASTROINTESTINAL TRACT CANCER PATIENTS .....	21
Derevyanko M.A., Klebanova N.A., Sedakova V.A., Klebanov A.V., Rjabceva S.N.	
METALLOTHIONEINS PROTECT AGAINST OBESE-INDUCED OXIDATIVE STRESS IN YOUNG WOMEN .....	22
Falfushynska H., Horyn O., Khoma V., Buyak B., Kasianchuk N., Fediuk O., Gnatyshyna L., Stoliar O.	
VITAMIN D: A POTENTIAL BIOMARKER FOR MORE AGGRESSIVE PROSTATE CANCER .....	23
Galunsk B., Roussev B., Gerova D., Kossev P.	
RELATIVE GENE EXPRESSION OF SELECTED MIRNAS AS POSSIBLE BIOMARKERS IN COLORECTAL CANCER STAGE DEVELOPMENT .....	24
Pantelis Dimaras, Oskan Tasinov, Desislava Ivanova, Yoana Kiselova-Kaneva, Maria Tzaneva, Nadezhda	
MOLECULAR PROFILING OF PROSTATE TUMORS .....	25
Gerashchenko G.V., Kashuba V.I.	
ALPHA-FETOPROTEIN OF UMBILICAL CORD BLOOD AS A PREDICTOR OF LIFE DYSFUNCTION IN NEWBORN INFANTS WITH PERINATAL PATHOLOGY .....	25
Godovanets O., Godovanets O.I., Babintseva A., Volosivska Yu.	
THE EFFECT OF BISOPROLOL ON DISEASE COURSE FOR PATIENTS WITH HIGH SST2 LEVELS AND ACUTE MYOCARDIAL INFARCTION .....	27
Kopytsya N. P., Hilova Ya. V., Kobets A.V.	
PARAMETERS OF DAILY BLOOD PRESSURE MONITORING AND SERUM LEVELS OF CHEMERIN AND NESFATIN-1 IN HYPERTENSIVE PATIENTS WITH OBESITY .....	28
Ivanchenko S.V.	

## References:

1. Boryak, V.P., Trybrat, T.A., Treumova, S.I., Niemchenko, L.B. & Veselij, D.I., 2015. Vychennya faktoriv ryzyku khronichnoho obstruktyvnoho zakhvoryuvannya lehen na foni metabolichnoho syndromu. *Visnyk problem biolohiyi i medytsyny*. 3, 1(122), pp.15-17.
2. Trybrat, T.A., Shut, S.V. & Sakevych, V.D., 2015. Metabolichnyy syndrom v praktytsi simeynoho likarya. *Visnyk problem biolohiyi i medytsyny*. 2, 4(121). pp. 36-38.
3. Barnes, P.J., 2010. Chronic Obstructive Pulmonary Disease: Effects beyond the Lungs. *PLoS Med*. 7(3): e1000220. <https://doi.org/10.1371/journal.pmed.1000220>
4. Treumova, S.I., Petrov, Ye.Ye. & Boryak, V.P., 2015. Khronichne obstruktyvne zakhvoryuvannya lehen u poyednanni z metabolichnym syndromom. *Visnyk problem biolohiyi i medytsyny*. 1(117), pp. 33-36.

*Key words: chronic non-specific lung diseases, pulmonary heart disease, heart failure, hypertrophy of the myocardium, myocardial atrophy, lipid peroxidation, antioxidant defense.*

Accepted for printing on 16 Sept 2018

DOI: 10.29256/v.02.02.2018.escbm09

## RELATION OF GROWTH-DIFFERENTIATION FACTOR-15 LEVELS AND NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Alexander A. Kremzer<sup>1</sup>, Ivan M. Fushtey<sup>2</sup>, Alexander A. Berezin<sup>2</sup>

<sup>1</sup> Medical University, Zaporozhye, Ukraine

<sup>2</sup> Medical Academy of Postgraduate Education, Zaporozhye, Ukraine

Background: risk stratification of patients with established type 2 diabetes mellitus (DM) is under scientific discussion and appears to be controversial issue.

The objective: to investigate relationship between levels of growth differentiation factor-15 (GDF-15) and circulating number of endothelial progenitor cells (EPCs) with angiopoietic phenotypes: CD34<sup>+</sup>CD14<sup>+</sup>CD309<sup>+</sup>, and CD34<sup>+</sup>CD14<sup>+</sup>CD309<sup>+</sup>Tie2<sup>+</sup> in patients with type 2 DM.

**Materials and Methods.** The study retrospectively involved 76 patients with type 2 DM aged 38 to 55 years and 30 healthy volunteers. Data collection included demographic and anthropometric information, hemodynamic performances and biomarkers of the disease. EPCs' populations were determined by flow cytometry.

**Results.** The levels of GDF-15 in peripheral blood of diabetics associated with age ( $r = 0.31$ ,  $P = 0.044$ ), high-sensitive C-reactive protein [hs-CRP] ( $r = 0.40$ ,  $P = 0.001$ ), smoking ( $r = 0.38$ ,  $P = 0.001$ ), body mass index [BMI] ( $r = 0.34$ ,  $P = 0.001$ ), LDL cholesterol ( $r = 0.28$ ,  $P = 0.001$ ), glycated hemoglobin [HbA1c] ( $r = -0.28$ ,  $P = 0.001$ ), number of CV risk factors ( $r = 0.26$ ,  $P = 0.001$ ). In univariate logistic regression analysis we found that level of GDF-15  $\geq 618$  pg/mL, hs-CRP  $\geq 7.12$  mg/L, HbA1c  $\geq 6.4\%$ , fasting glucose  $\geq 6.7$  mmol/L, and BMI  $\geq 27.3$  kg/m<sup>2</sup> predicted deficiency of both angiopoietic phenotypes of EPCs. In multivariate logistic regression model GDF-15  $\geq 618$  pg/mL demonstrated the best odds ratio values for declining of EPCs in diabetics in comparison with other predictors including BMI, HbA1c and hs-CRP.

In conclusion, GDF-15 was extremely evaluated in type 2 DM population to healthy volunteers and it was an independent factor that contributes to mobilization and probably proliferation of endothelial precursors with high angiopoietic activity.

*Key words: growth differentiation factor-15; endothelial progenitor cells; type 2 diabetes mellitus.*

Accepted for printing on 19 Sept 2018

DOI: 10.29256/v.02.02.2018.escbm10

## MARKERS OF ENDOTHELIAL INJURIES IN PATIENTS WITH CORONARY HEART DISEASE AND AUTOIMMUNE THYROIDITIS

Chekalina N., Kazakov Yu., Vesnina L., Mamontova T., Yushchenko Yu., Berkalo L.

Higher State Educational Institution of Ukraine

"Ukrainian Medical Stomatological Academy", Ukraine

According to WHO, coronary heart disease (CHD) has been on the top of the list of 10 leading causes of death in the world over the years, and its share is 12.8% [1,2]. CHD mortality among working age population is 28.3% [2]. At the same time, there is a significant increase in autoimmune thyroiditis (AIT) in society: particularly, in Ukraine the prevalence of AIT has increased by 68% over the past 10 years [3,4]. Today, endothelial dysfunction (ED) is considered to be the pathogenetic basis for the formation of atherosclerotic vascular lesions. ED, formed in conditions of chronic systemic inflammation (CSI), is the earliest stage of atherogenesis, and it plays a leading role in the progression of

vascular changes and development of atherothrombosis<sup>[5]</sup>. At the same time, CSI is the pathogenetic basis of AIT<sup>[3]</sup>. AIT potentiates the development of atherosclerosis (ASVD), creating an immune-inflammatory environment, regardless of the development of hypothyroidism, which is an indispensable consequence of AIT and results in the progression of cardiovascular disease<sup>[6]</sup>. The above-mentioned determines the relevance of the search for indicative markers of endothelial injuries in conditions of the specified pathology for optimization of diagnosis, evaluation of the course and efficacy of therapeutic measures. Lately, significant scientific experience has been accumulated on the determination of ED by the level of circulating endothelial microparticles (EMP) in the bloodstream<sup>[7,8]</sup>. By the number of EMPs with the corresponding types of molecular antigenic markers classified by the CD system (from the English "cluster designation"), it is possible to make a conclusion about the condition of the cells producing them<sup>[7]</sup>. The purpose of our study was to study the condition of vascular endothelium in patients with CHD and CHD in combination with AIT at the level of EMP CD32<sup>+</sup>CD40<sup>+</sup> and to compare the obtained data with the level of systemic inflammation.

**Materials and methods.** One-time, open-label clinical trial was conducted — single group study. It involved 175 people of both sexes: 115 patients with CHD: stable angina pectoris, FC II, HF 0-I (Study Group 1), 30 patients with AIT in euthyroid state (Study Group 2) and 30 healthy individuals, amounted to the control group. The criteria for inclusion into the research were men and women's age of 40-74, the presence of CHD: angina pectoris, FC II, absence of destabilizing flow of CHD for at least two months, as well as the presence of concomitant AIT in the stage of euthyroidism, and the patient's informed consent to participate in the research. The exclusion criteria were the presence of Stage 2 hypertension, Stage 1 chronic heart failure (CHF), complications of cardiac rhythm and conduction, rheumatic diseases, anemia, diabetes mellitus, chronic liver and kidney disease with functional impairment, cancer. To all participants of the study a determination of the amount of EMPs in peripheral blood with expression of CD32 and CD40 antigens was made by flow cytometry using monoclonal antibodies<sup>[9]</sup>. CD32 (FCγRIIB) is an immunoglobulin superfamily receptor, CD40 belongs to the tumor necrosis factor alpha (TNFα) superfamily, both antigens play an important role in inflammatory signaling<sup>[10, 11]</sup>. TNFα was studied as a CSI marker by the immunoenzymatic method<sup>[12]</sup>.

**Results.** In patients from Study Group 1 (CHD) and Study Group 2 (CHD in combination with AIT), the content of EMP CD32<sup>+</sup>CD40<sup>+</sup> in peripheral blood was significantly higher than in healthy individuals, who had the value of this index of  $1.3 (1.05-2.11) \times 10^7/L$ . At the same time, the content of EMP CD32<sup>+</sup>CD40<sup>+</sup> in patients from Study Group 2 was significantly higher than in Study Group 1, and was  $2.62 (1.50-6.10) \times 10^7/L$  versus  $1.8 (1.12-4.96) \times 10^7/L$  ( $p=0.036$ ). It indicates a high level of inflammatory activation of the endothelium in conditions of chronic autoimmune inflammation. When comparing the results of study of EMP CD32<sup>+</sup>CD40<sup>+</sup> in all the groups, it was found that a value greater than  $2.5 \times 10^7/L$  indicates endothelial injury. The sensitivity (Se) and specificity (Sp) of the endothelial injury detection method were calculated using EMP CD32<sup>+</sup>CD40<sup>+</sup> in AIT in combination with CHD: Se was 82%, Sr – 83%. In patients of both groups, the level of TNFα in the blood was elevated, while with the combination of CHD and AIT the level of TNFα was significantly higher than in patients with CHD alone ( $10.54 \pm 2.42$  pg/mL versus  $8.53 \pm 3.24$  pg/mL). A close correlation between values of EMP CD32<sup>+</sup>CD40<sup>+</sup> and TNFα in patients with CHD in combination with AIT ( $r=0.81$ ,  $p<0.05$ ) was found out. According to the data, the value of EMP  $> 2.5 \times 10^7/L$  corresponds to the value of TNFα  $> 7.9$  pg/mL. Se and Sr showed an increase in TNFα  $> 7.9$  pg/mL as a marker, confirming the presence of endothelial injury in CHD in combination with AIT: Se was 100%, Sr – 82%.

The amount of EMP CD32<sup>+</sup>CD40<sup>+</sup> in the blood is a reliable marker of inflammatory activation and destruction of vascular endothelium in CHD and CHD in combination with AIT. With a combination of CHD and AIT, increasing the TNFα content is a probable marker of inflammatory endothelial injury.

The use of the indicator of EMP CD32<sup>+</sup>CD40<sup>+</sup> in the blood, as well as the study of EMP with other antigenic molecular markers, will expand the understanding the mechanisms of development and course of diseases with vascular injuries in the pathogenesis, and develop effective diagnostic approaches.

Determining the amount of EMP CD32<sup>+</sup>CD40<sup>+</sup> in the blood is a highly sensitive method for verifying inflammatory endothelial injury, with CHD and CHD in combination with AIT in particular, and may be recommended for widespread use with the aim of early diagnosis of vascular injury, its progression, and to evaluate the efficacy of therapeutic measures.

#### References:

1. Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., et al., 2013. 2013 ESC guidelines on the management of stable coronary artery disease. *Eur Heart J.* 34, pp. 2949–3003.
2. Kovalenko, V.M. & Kornatsky, V.M., 2015. *Stres i hvoroby systemy krovoobigu*. Kiev: SI NSC Institute of Cardiology named after Acad. MD Strazhesko, 354 p.
3. Vanderpump, M.P.J., 2011. The epidemiology of thyroid disease. *Br Med Bull.* 99(1), pp. 39-51.
4. Karachentsov, Y.U., 2015. *Chotirnadtsiyati Danilevski chitannya. Materlali konferentsiyi z mizhnarodnoyu uchastyu: dosyagnennya ta perspektivi eksperimentalnoyi ta klinichnoyi endokrinologiyi*. Kharkiv, pp. 104-172.
5. Brunetti, N.D., Correale, M., Pellegrino, P.L, Munno, I., Cuculo, A., De Gennaro, L, Gaglione, A & Di Biase, M., 2014. Early inflammatory cytokine response: A direct comparison between spontaneous coronary plaque destabilization vs angioplasty induced. *Atherosclerosis.* 236(2), pp. 456-460.
6. Ganesh, B. B., Bhattacharya, P., Gopisetty, A. & Prabhakar, B. S., 2011. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. *J Interferon Cytokine Res.* 31(10), pp. 721–731.
7. Loyer, X., Vion, A.C., Tedgui, A. & Boulanger, C.M., 2014. Microvesicles as cell-cell messengers in cardiovascular diseases. *Circ Res.* 114(2), pp. 345-353.

8. Berezin, A.E. & Kruzliak, P., 2014. Circulating endothelial apoptotic microparticles as a new marker of cardiovascular risk (literature review). *Ukr. med. Chasopis.* 5(103), pp. 83-87.
9. Kutsenko, N.L., Savchenko, I.G., Kaydasheva, E.I., Kutsenko, L.A., Solochina, I.L. & Kaydashev I.P., 2011. Determination of circulating CD32<sup>+</sup> CD40<sup>+</sup> microparticles — modification of degradation assessment of endothelial cells. *Clinical Laboratory Diagnostics.* 7, pp. 20-23.
10. Tanigaki, K, Sundgren N., Khera, A., Vongpatanasin, W., Mineo, C. & Shaul, P.W., 2015. Fcy Receptors and Ligands and Cardiovascular Disease. *Circ Res.* 116(2), pp. 368–384.
11. Petersa, A.L., Stunzb, L.L. & Bishopa, G.A., 2009. CD40 and autoimmunity: The dark side of a great activator. *Seminars in Immunology.* 21(5), pp. 293–300.
12. Hashizume, M. & Mihara M., 2012. Atherogenic effects of TNF- $\alpha$  and IL-6 via up-regulation of scavenger receptors. *Cytokine.* 58(3), pp. 424–430.

Key words: coronary heart disease, autoimmune thyroiditis, endothelial dysfunction, chronic systemic inflammation, circulating endothelial microparticles, tumor necrosis factor  $\alpha$ .

Accepted for printing on 31 Aug 2018

DOI: 10.29256/v.02.02.2018.escbm11

### PREDICTIVE RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN ON EFFECT OF GINKGO BILOBA EXTRACT-761 IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER

Jithendra Chimakurthy<sup>1\*</sup>, Talasila Egk Murthy<sup>2</sup>, Prakash V Diwan<sup>3</sup>,

<sup>1</sup>Department of Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research University, India.

<sup>2</sup>Department of Pharamceutics, Bapatla College of Pharmacy, India.

<sup>3</sup>Central Research Laboratory, India.

Drugs of herbal origin have proven to be effective in many anxiety disorders. EGb-761, EGB-761, a standardized extract of the *Ginkgo biloba* [Leaf] containing 24% of flavone glycosides (quercetin, kaempferol and iso rhamnetin) and 6% of terpenes (gingkolides and bilobalides) is an effective anxiolytic, neuroprotective and nootropic agent, despite its influential roles in various ailments of central nervous system, the data available in the treatment of obsessive compulsive disorder (OCD), a debilitating anxiety disorder and fourth most common forms of mental illness with server memory impairment, is scarce.

**Materials and Methods.** In this study, we evaluated the effect of *Ginkgo biloba* extract, EGb-761 50, 100 and 200 mg/kg on OCD using quinpirole (0.5 mg/kg) induced compulsive checking in rats and marble burying behaviour in mice, Rats were trained using Morris water maze apparatus before the induction of OCD and was used to evaluate the effect on spatial memory, the compulsions induced with quinpirole were assessed using an open field, on the last day of the treatment various behavioural parameters at each object were analysed such as: Frequency and duration of stops, Number of visits to other objects on successive return to each object and ritualistic behaviour for a period of 55 min.

**Results.** The effect on memory was evaluated based on the retention of the learned task i.e. time taken for the identification of the platform in Morris water maze apparatus and the underlying mechanisms are predicted based on the studies of brain monoamines such as dopamine and serotonin. EGb-761 at 100 and 200 mg/kg had shown significant improvement against quinpirole induced compulsions, a protective effect on memory task was observed in EGb treated rats. This could be attributed to the increase in serotonin and decrease in the dopamine levels. The interaction between the dopaminergic and serotonergic systems in the mid-brain regions i.e. substantia nigra and ventral tegmentum, with dopaminergic neurons being targets for serotonin cells explains the involvement of serotonin and dopamine in OCD. Activation of 5HT<sub>1A</sub> (autoreceptor) inhibits dopamine release in the dorsal striatum and enhances dopamine release in nucleus accumbens. This explains the possible mechanism of the effect of SSRI's in the treatment of DA agonist induced OCD, as quinpirole is agonist to D<sub>2</sub> and D<sub>3</sub> receptors in the striatum which in turn increases the dopamine levels. The increase in the serotonin concentration with EGb-761, its role on 5HT<sub>1A</sub>-autoreceptors, which inhibit dopamine release and studies, on sertraline that it decreases the extracellular dopamine in the striatum, further supports the observation and the resulting decrease in dopamine levels observed in the present study, contributes to the protective effect of EGb and paroxetine in OCD. The protective effect of EGb-761 in the treatment of OCD is evident with both the performance on the open field and marble burying behaviour. The number of marbles buried by the end of 10 min was calculated after 1, 14, 28 days of treatment for all the groups.

Key words: Obsessive-compulsive disorder, *Ginkgo biloba*, memory, serotonin and dopamine.

Accepted for printing on 24 Jun 2018